16/10/2025

ASX Release

EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

SHARE PURCHASE PLAN CLOSING DATE REMINDER

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to advise that the Share Purchase Plan (SPP) announced on 17 September 2025, has received applications well in excess of the targeted raising amount of $1 million.

The SPP allows for oversubscription of an additional $1 million, with a maximum SPP of $2 million. The Company advises that modest headroom remains in the additional oversubscription amount.

The Company may close the SPP early to minimise the scale back of applications. Eligible Shareholders are encouraged to submit their Application Forms as early as possible to take advantage of the remaining SPP capacity.

THE SPP WILL REMAIN OPEN UNTIL 5:00 PM (AEDT) ON FRIDAY, 23 OCTOBER 2025, UNLESS CLOSED EARLY.

Eligible Shareholders should refer to the SPP Access Letter released on the ASX on 30 September 2025 for details on how to download personalised Application Forms.

SPP Offer

Eligible Shareholders can participate in the Company's share purchase plan by subscribing for fully paid ordinary shares in the Company (Shares) up to a maximum subscription of A$30,000 at an issue price of A$1.94 per Share (SPP Offer). The SPP Offer is offered to Eligible Shareholders under an offer booklet in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (Offer Booklet).

Eligible Shareholders that apply for Shares under the SPP Offer will also be invited to subscribe for free-attaching quoted options exercisable at $3.40 each and expiring 2 years from the issue date (SPP Options) on the basis of three (3) SPP Options for every four (4) Shares applied for and issued under the SPP Offer (SPP Options Offer).

The SPP Options Offer is offered to Eligible Shareholders under a prospectus lodged by the Company (Prospectus).

Eligible Shareholders are shareholders who were registered as the holder of Shares as at 7:00pm AEST on Tuesday, 16 September 2025 ("Record Date") and whose registered address is in Australia and New Zealand.

The Board would like to thank shareholders for their strong support of EMVision.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys	Scott Kirkland
Investors & Media	CEO and Managing Director
+61 400 400 380	+61 2 8667 5337
andrew.keys@keysthomas.com	skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision’s current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.